DiamondARSilvaNDTomlinsonGPencharzPBFeldmanBMMooreAMLingSCWalesPW. Role of parenteral lipids in the development of advanced intestinal failure–associated liver disease in infants. JPEN J Parenter Enteral Nutr. 2011;X:[IN PRESS].
2.
NasrAAvitzurYNgVDe SilvaNWalesP. The use of conjugated hyperbilirubinemia greater than 100 micromol/L as an indicator of irreversible liver disease in infants with short bowel syndrome. J Pediatr Surg. 2007;42:359-362.
3.
AllardyceD. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet. 1982;154:641-647.
4.
ClaytonPBowronAMillsKMassoudACasteelsMMillaP. Phytosterolemia in children with parenteral nutrition–associated cholestatic liver disease. Gastroenterology. 1993;105:1806-1813.
5.
ClaytonPWhitfieldPIyerK. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition. 1998;14:158-164.
6.
IyerKSpitzLClaytonP. BAPS prize lecture: New insight into mechanisms of parenteral nutrition–associated cholestasis: role of plant sterols. British Association of Paediatric Surgeons. J Pediatr Surg. 1998;33:1-6.
7.
CarterBTaylorOPrendergastD. Stigmasterol, a soy lipid–derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res. 2007;62:301-306.
8.
CarterBAShulmanRJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:277-287.
9.
ColombVJobert-GiraudALacailleFGouletOFournetJRicourC. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24:345-350.
10.
CavicchiMBeauPCrennPDegottCMessingB. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132:525-532.
11.
CoberMTeitelbaumD. Prevention of parenteral nutrition–associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010;15:330-333.
12.
GuraKDugganCCollierS. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118:197-201.
13.
PuderMValimCMeiselJA. Parenteral fish oil improves outcomes in patients with parenteral nutrition–associated liver injury. Ann Surg. 2009;250:395-402.
14.
DiamondIRSterescuAPencharzPBKimJHWalesPW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48:209-215.
15.
de MeijerVEGuraKMLeHDMeiselJAPuderM. Fish oil–based lipid emulsions prevent and reverse parenteral nutrition–associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009;33:541-547.
16.
SudanDLKaufmanSSShawBWJr. Isolated intestinal transplantation for intestinal failure. Am J Gastroenterol. 2000; 95:1506-1515.
17.
FielMISauterBWuHS. Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. Clin Gastroenterol Hepatol. 2008;6: 926-933.
18.
FielMIWuHSIyerKRodriguez-LaizGSchianoTD. Rapid reversal of parenteral-nutrition-associated cirrhosis following isolated intestinal transplantation. J Gastrointest Surg. 2009;13: 1717-1723.
